Galectin Therapeutics (NASDAQ:GALT) Given Neutral Rating at HC Wainwright

Galectin Therapeutics (NASDAQ:GALT)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Wednesday,Benzinga reports.

Separately, StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 30th.

Galectin Therapeutics Stock Up 3.3 %

GALT opened at $1.26 on Wednesday. The company has a market capitalization of $79.08 million, a PE ratio of -1.73 and a beta of 0.69. The firm has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $1.95. Galectin Therapeutics has a 52 week low of $0.73 and a 52 week high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Monday, March 31st. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, sell-side analysts expect that Galectin Therapeutics will post -0.73 earnings per share for the current year.

Hedge Funds Weigh In On Galectin Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of GALT. Sovran Advisors LLC bought a new stake in Galectin Therapeutics in the fourth quarter worth $240,000. Soltis Investment Advisors LLC bought a new stake in shares of Galectin Therapeutics in the 3rd quarter worth about $387,000. Retirement Guys Formula LLC boosted its stake in shares of Galectin Therapeutics by 143.4% during the 4th quarter. Retirement Guys Formula LLC now owns 155,343 shares of the company’s stock worth $200,000 after purchasing an additional 91,526 shares during the period. LPL Financial LLC grew its holdings in Galectin Therapeutics by 69.6% during the 4th quarter. LPL Financial LLC now owns 138,928 shares of the company’s stock valued at $179,000 after purchasing an additional 57,020 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new stake in Galectin Therapeutics in the 3rd quarter worth about $117,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.